228 related articles for article (PubMed ID: 22248469)
1. TGFBI promoter hypermethylation correlating with paclitaxel chemoresistance in ovarian cancer.
Wang N; Zhang H; Yao Q; Wang Y; Dai S; Yang X
J Exp Clin Cancer Res; 2012 Jan; 31(1):6. PubMed ID: 22248469
[TBL] [Abstract][Full Text] [Related]
2. Frequent promoter hypermethylation of TGFBI in epithelial ovarian cancer.
Kang S; Dong SM; Park NH
Gynecol Oncol; 2010 Jul; 118(1):58-63. PubMed ID: 20421128
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer.
Palomeras S; Diaz-Lagares Á; Viñas G; Setien F; Ferreira HJ; Oliveras G; Crujeiras AB; Hernández A; Lum DH; Welm AL; Esteller M; Puig T
Breast Cancer Res; 2019 Jul; 21(1):79. PubMed ID: 31277676
[TBL] [Abstract][Full Text] [Related]
4. ß3 integrin modulates transforming growth factor beta induced (TGFBI) function and paclitaxel response in ovarian cancer cells.
Tumbarello DA; Temple J; Brenton JD
Mol Cancer; 2012 May; 11():36. PubMed ID: 22640878
[TBL] [Abstract][Full Text] [Related]
5. Expression and promoter methylation status of mismatch repair gene hMLH1 and hMSH2 in epithelial ovarian cancer.
Zhang H; Zhang S; Cui J; Zhang A; Shen L; Yu H
Aust N Z J Obstet Gynaecol; 2008 Oct; 48(5):505-9. PubMed ID: 19032668
[TBL] [Abstract][Full Text] [Related]
6.
Seok Y; Lee WK; Park JY; Kim DS
Mol Cells; 2019 Feb; 42(2):161-165. PubMed ID: 30726660
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic regulation of putative tumor suppressor TGFBI in human leukemias.
Fang H; Liu J; Guo D; Liu P; Zhao Y
Chin Med J (Engl); 2014; 127(9):1645-50. PubMed ID: 24791868
[TBL] [Abstract][Full Text] [Related]
8. [Effects of 5-Aza-2'-deoxycytidine and trichostatin A on DNA methylation and expression of hMLH1 in ovarian cancer cell line COC1/DDP].
Meng CF; Dai DQ; Guo KJ
Ai Zheng; 2008 Dec; 27(12):1251-5. PubMed ID: 19079988
[TBL] [Abstract][Full Text] [Related]
9. The Role of Abnormal Methylation of Wnt5a Gene Promoter Regions in Human Epithelial Ovarian Cancer: A Clinical and Experimental Study.
Jin P; Song Y; Yu G
Anal Cell Pathol (Amst); 2018; 2018():6567081. PubMed ID: 30079293
[TBL] [Abstract][Full Text] [Related]
10. Methylation screening of the TGFBI promoter in human lung and prostate cancer by methylation-specific PCR.
Shah JN; Shao G; Hei TK; Zhao Y
BMC Cancer; 2008 Oct; 8():284. PubMed ID: 18834524
[TBL] [Abstract][Full Text] [Related]
11. The TGFBI gene and protein expression in topotecan resistant ovarian cancer cell lines.
Wojtowicz K; Świerczewska M; Nowicki M; Januchowski R
Adv Med Sci; 2023 Sep; 68(2):379-385. PubMed ID: 37806183
[TBL] [Abstract][Full Text] [Related]
12. Clinical implications of REST and TUBB3 in ovarian cancer and its relationship to paclitaxel resistance.
Gao S; Zhao X; Lin B; Hu Z; Yan L; Gao J
Tumour Biol; 2012 Oct; 33(5):1759-65. PubMed ID: 22684772
[TBL] [Abstract][Full Text] [Related]
13. Clinical importance and therapeutic implication of E-cadherin gene methylation in human ovarian cancer.
Wu X; Zhuang YX; Hong CQ; Chen JY; You YJ; Zhang F; Huang P; Wu MY
Med Oncol; 2014 Aug; 31(8):100. PubMed ID: 24973953
[TBL] [Abstract][Full Text] [Related]
14. RUNX3 gene methylation in epithelial ovarian cancer tissues and ovarian cancer cell lines.
Zhang S; Wei L; Zhang A; Zhang L; Yu H
OMICS; 2009 Aug; 13(4):307-11. PubMed ID: 19645591
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic profiling and mRNA expression reveal candidate genes as biomarkers for colorectal cancer.
Zhang H; Dong S; Feng J
J Cell Biochem; 2019 Jun; 120(6):10767-10776. PubMed ID: 30672027
[TBL] [Abstract][Full Text] [Related]
16. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
18. Demethylation of HIN-1 reverses paclitaxel-resistance of ovarian clear cell carcinoma through the AKT-mTOR signaling pathway.
Ho CM; Huang CJ; Huang SH; Chang SF; Cheng WF
BMC Cancer; 2015 Oct; 15():789. PubMed ID: 26497956
[TBL] [Abstract][Full Text] [Related]
19. XAF1 is frequently methylated in human esophageal cancer.
Chen XY; He QY; Guo MZ
World J Gastroenterol; 2012 Jun; 18(22):2844-9. PubMed ID: 22719195
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of SOX2 is involved in paclitaxel resistance of ovarian cancer via the PI3K/Akt pathway.
Li Y; Chen K; Li L; Li R; Zhang J; Ren W
Tumour Biol; 2015 Dec; 36(12):9823-8. PubMed ID: 26159849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]